Industry
FDA Moves to Rehire Some Recently Fired Employees Amid Backlash
FDA, layoffs, rehiring, Trump administration, medical device industry, public health agencies
Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation
Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry
Trump’s Healthcare Nominees Pledge to Divest Industry Investments Amid Controversy
Trump administration, healthcare appointments, NIH, CMS, divestment, industry ties, Jay Bhattacharya, Mehmet Oz, Robert F. Kennedy Jr.
Illumina’s Double-Edged Sword: Navigating US-China Trade Tensions
Illumina, China, tariffs, trade tensions, DNA sequencing, unreliable entity list, biotech industry, BIOSECURE Act
Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints
Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges
Thermo Fisher Scientific Continues Workforce Reduction with 300 Layoffs in Massachusetts
Thermo Fisher Scientific, layoffs, Massachusetts, viral vector production, workforce reduction, biotechnology industry, cost-cutting measures
Zentalis Pharmaceuticals Cuts Workforce by 40% to Advance WEE1 Inhibitor to Registrational Trial
Zentalis Pharmaceuticals, layoffs, WEE1 inhibitor, azenosertib, clinical trials, cancer treatment, biotech industry
Sionna and Odyssey Therapeutics Kick Off 2025 Biotech IPO Wave with SEC Filings
Sionna Therapeutics, Odyssey Therapeutics, IPO filings, biotech industry, JPM Healthcare Conference, 2025 IPO market
Key Takeaways from #JPM25: Strategic Partnerships and Acquisitions Dominate the JP Morgan Healthcare Conference
JP Morgan Healthcare Conference, #JPM25, biopharma industry, acquisitions, partnerships, Eli Lilly, Zealand Pharma, GSK, Scorpion Therapeutics
IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data
IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry